Importance Clinical evidence supports effectiveness of cannabidiol for treatment-resistant
seizures in Dravet syndrome, but this trial is the first to evaluate the 10-mg/kg/d dose …

Background The Dravet syndrome is a complex childhood epilepsy disorder that is
associated with drug-resistant seizures and a high mortality rate. We studied cannabidiol for …

Objective Add‐on cannabidiol (CBD) significantly reduced seizures associated with Dravet
syndrome (DS) in a randomized, double‐blind, placebo‐controlled trial: GWPCARE1 Part B …

Objective Add‐on cannabidiol (CBD) reduced seizures associated with Dravet syndrome
(DS) in two randomized, double‐blind, placebo‐controlled trials: GWPCARE1 Part B …

Background Dravet syndrome (DS) is one of the most severe forms of drug-resistant
epilepsy and available interventions fail to control seizures in most patients. Cannabidiol …

Objective To evaluate the safety and preliminary pharmacokinetics of a pharmaceutical
formulation of purified cannabidiol (CBD) in children with Dravet syndrome. Methods …

Background Dravet syndrome (DS) is a severe developmental and epileptic encephalopathy
characterized by drug-resistant, lifelong seizures. The management of seizures in DS has …

Dravet syndrome is a rare but severe epilepsy syndrome that begins in the first year of life
with recurrent seizures triggered by fever that are typically prolonged and hemiclonic. The …

Background Purified cannabidiol is a new antiepileptic drug that has recently been
approved for use in patients with Lennox–Gastaut and Dravet syndromes, but most …

Antiseizure medications (ASMs) are the mainstay for the treatment of seizure disorders.
However, about one-third of people with epilepsy remain refractory to current ASMs …